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Abstract 37 
Background China has an ageing population with an increasing number of 38 adults aged ≥60 years. Influenza causes a heavy disease burden in older adults, 39 but can be alleviated by vaccination. We assessed the cost-effectiveness of a 40 potential government-funded seasonal influenza vaccination program in older 41 adults in China. 42 
Methods We characterized the health and economic impact of a fully-funded 43 influenza vaccination program for older adults using China specific influenza 44 disease burden, and related cost data, etc. Using a decision tree model, we 45 calculated the incremental costs per quality-adjusted life year (QALY) gained of 46 vaccination from the societal perspective, at a willingness-to-pay threshold 47 equivalent to GDP per capita (US$8,840).  48 
Findings Compared to current self-paid vaccination, a fully-funded vaccination 49 program is expected to prevent 19,812 (95% uncertainty interval, 7,150-35,783) 50 influenza-like-illness outpatient consultations, 9,418 (3,386-17,068) severe acute 51 respiratory infection hospitalizations and 8,800 (5,300-11,667) respiratory 52 excess deaths due to influenza, and gain 70,212 (42,106-93,635) QALYs. 53 Nationally, the incremental costs per QALY gained of the vaccination program is 54 US$4,832 (3,460-8,307), with a 98% probability of being cost-effective. However, 55 variations exist between geographical regions, with Northeast and Central China 56 having lower probabilities of cost-effectiveness.  57 
Interpretation Our results support the implementation of a government fully-58 funded older adult vaccination program in China. The regional analysis provides 59 results across settings that may be relevant to other countries with similar 60 disease burden and economic status, especially for low- and middle-income 61 countries where such analysis is limited. 62 
Funding National Science Fund for Distinguished Young Scholars, and UK 63 National Institute of Health Research. 64 
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1. Introduction 65 
Seasonal influenza is a major cause of mortality, with recent estimates suggesting 66 that 291 000–646 000 influenza-associated respiratory deaths occur globally 67 each year1. Older adults are at increased risk of hospitalization or death if 68 infected, and thus are included in the recommended groups for annual influenza 69 vaccination by the World Health Organization (WHO)2. The World Health 70 Assembly set a target of attaining vaccination coverage of 75% in this group by 71 2010 3. Most high income countries and many upper-middle income countries, 72 like Thailand and Brazil, have incorporated seasonal influenza vaccination for 73 older adults into their National Immunization Program, which has significantly 74 increased vaccination uptake4-6.  75 
As the world's most populous country, China has more adults ≥ 60 years (>210 76 million in 2016) than any other country, accounting for nearly a quarter of the 77 global total. China is also ageing rapidly; adults ≥60 years account for 15% of the 78 population in 20167 and will increased to 26% by 20308. Influenza caused 66-79 105 severe acute respiratory infections (SARI) hospitalizations per 100,000 80 
adults ≥60 years in China9,10. Annually, over 80% of influenza-related excess 81 deaths occurred in older adults11,12, with an average excess respiratory mortality 82 rate per season estimated at 38·5 (95% confidence interval, 95%CI 36·8-40·2) 83 per 100,000 person between 2010-1512. However, there is no nationwide 84 government-funded influenza vaccination program for older adults in China, and 85 the cost of vaccination is completely borne by individuals. This self-paid 86 vaccination system contributes to an extremely low vaccine uptake of 4% in this 87 age group, far behind the target of 75%13. Only a handful of relatively wealthy 88 cities provide free influenza vaccination for older adults paid by local 89 governments14. For example, since 2007, Beijing has provided free influenza 90 vaccination to older adults, leading to the uptake reaching 39% in 201215.  91 
Following a health scare involving improper refrigeration of transported vaccines 92 
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sold privately nationwide in 201616, the State Council of China recommended 93 acceleration of the inclusion into the National Immunization Program of vaccines 94 currently sold in the private sector17. The new vaccine administration law in 95 2019 requires establishing a ‘national dynamic adjustment mechanism’ for 96 inclusion/exclusion of vaccines into National Immunization Program18. Both the 97 State Council and National Immunization Advisory Committee also 98 recommended taking into consideration the cost-effectiveness of vaccination 99 alongside traditional considerations of vaccine efficacy and safety for vaccine 100 policy-making19. 101 
A systematic review of cost-effectiveness studies of influenza vaccination showed 102 that globally a third of studies (8/27) found vaccination in older adults to be 103 cost-saving, and most of the remainder found vaccination to be cost-effective20. 104 However, to date no comprehensive study has been conducted in mainland China, 105 where the economic impact of fully-funded vaccination programs may differ 106 greatly across regions due to large variations in influenza seasonality, disease 107 burden, demographic structure, and social economic development11,21,22. Hence, 108 the objective of this study is to answer the question of whether a fully-funded 109 influenza vaccination program for nearly a quarter of the world’s older adult 110 population is an efficient use of resources in mainland China, and to further 111 explore whether variations in this result exist across geographical regions.  112 
2. Methods 113 
Following WHO guidance on the economic evaluation of influenza vaccination23, 114 we performed a cost-effectiveness analysis of a government-funded influenza 115 vaccination program for adults ≥60 years compared to the status quo of 116 vaccinees paying out-of-pocket (hereafter “fully-funded vaccination program” 117 and "self-paid vaccination program" respectively) from the societal perspectives. 118 As most costs and effects due to influenza occur during a single influenza season, 119 we used a time horizon of one year, with the exception of tracking all the years of 120 
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life lost when a patient died of influenza-related causes.  121 
2.1 Decision tree model 122 
We developed a static decision tree model (Figure 1) to calculate the per person 123 costs of vaccination, per person costs due to influenza, and per person health 124 utility loss due to influenza. From these estimates, we estimated the impact of the 125 fully-funded program compared to self-paid vaccination on health and economic 126 outcomes at the regional and national level. We then used these outcomes to 127 calculate the incremental cost-effectiveness of the fully-funded program. Detailed 128 methods are shown in Supplementary Materials 1.  129 
As current vaccine coverage is only 4% and is concentrated in a few highly-130 developed cities with local government funding13, we assumed the probability of 131 being vaccinated was zero under the status quo. There is significant uncertainty 132 in the vaccine uptake that may be achieved in a potential fully-funded vaccination 133 program. The experience of Beijing showed that the uptake in older adults 134 increased substantially from 2% in 1999 to 39% in 201215,24 after fully-funded 135 influenza vaccination was offered in 2007. It is likely that the uptake in other less 136 densely-populated and developed provinces would not increase as quickly as 137 Beijing, the capital of China where residents likely to have greater access to 138 health care facilities. We therefore used a conservative coverage assumption of 139 30% in the analysis. 140 
An older adult is assumed to have a risk of acquiring a symptomatic influenza 141 infection annually. Someone with symptomatic influenza then has a probability of 142 seeking medical treatment, including self-medication, seeking healthcare in a 143 community or township health service center, consulting a doctor in an 144 outpatient department, or being hospitalized. Each infected person also has a 145 probability of dying of influenza-related causes, whether or not the person has 146 received healthcare. 147 
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The models were stratified by area (rural/urban) and geographical regions 148 (Figure S1: Northern, Northeast, Northwest, Eastern, Central, Southwest, and 149 Southern). All analyses were performed in R version 3·5·0 (https://www.r-150 project.org). 151 
2.2 Data sources 152 
2.2.1 Population 153 
The model tracked older adults aged 60-64, 65-69, 70-74, 75-79, and ≥80 years. 154 The age-specific population size in 2016 was obtained from the National Bureau 155 of Statistics in China, and stratified by area (rural/urban) using the proportion of 156 older persons living in urban areas reported in the 2010 Population Census of 157 China25. (Supplementary Materials 3) 158 
Older adults were further split into high- and low-risk groups. High-risk 159 individuals are defined as those with an increased risk of hospitalization or death 160 if infected by influenza due to underlying medical conditions as listed in the WHO 161 influenza vaccine guidelines, including chronic obstructive pulmonary disease, 162 asthma, diabetes, and chronic cardiac disease, etc.26 The remaining population 163 was categorized as low-risk. The probability of an older adult having at least one 164 underlying medical disease was estimated from the results of the China Health 165 and Retirement Longitudinal Study27,28, a nationally representative study on 166 health status in older people. (Supplementary Materials 4).  167 
2.2.2 Influenza-related disease burden 168 
Influenza-like-illness (ILI) consultations due to influenza 169 
The yearly average risk of ILI-related primary care or outpatient consultations 170 due to influenza in China was estimated to be 0·9 per 1,000 (95% CI 0·4-1·5) 171 between 2010-201529. The influenza-related ILI consultation risk varied 172 
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significantly cross provinces (Table S2), ranging from 10 to 690 per 100,000.  173 
Hospitalization 174 
It was found that influenza was associated with an estimated 89 (95%CI 85-90) 175 SARI hospitalizations per 100,000 for individuals ≥65 years during 2011-2012 in 176 Jingzhou (a city in Southern China)9. The rates were 105 (95%CI 85-129) and 66 177 (95%CI 50-86) per 100,000 people in Beijing (a province in Northern China) 178 during the 2014-2015 and 2015-2016 seasons, respectively10. In our study, the 179 influenza-related hospitalization rates in other Southern and Northern provinces 180 (Figure S1) were estimated using the local influenza-related ILI consultation rate 181 multiplied by the ratio of influenza-related SARI hospitalization rate to influenza-182 related ILI consultation rate separately in Jingzhou and Beijing9,10,29. 183 
Mortality 184 
The national average influenza-associated excess mortality attributable to 185 respiratory diseases was estimated to be 38·5 (95%CI 36·8-40·2) per 100,000 186 between 2010-2015 in China12. Variation (19.0-83.2/100,000) was observed 187 across provinces (Table S2). 188 
We found a clear positive relationship between Gross Regional Product per 189 capita and influenza-related ILI consultation risk (Pearson correlation 190 coefficient=0.83, p<0.05). This variation is likely to be explained by differences in 191 health care access or under-reporting. In the base case analysis, we used original 192 influenza-related ILI consultation and excess mortality rates as reported for each 193 province in the literatures 12,29. This assumes that the differences between 194 provinces are genuine and are explained by differences in influenza 195 epidemiology. 196 
The highest influenza-related ILI consultation risk occurs in Shanghai 197 (690/100,000), a high-income province with very good health care access and 198 
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surveillance system and. Accordingly, in the scenario analyses, we assumed 199 
every province has the same risk as Shanghai based on the “under-reporting” 200 hypothesis or assumed the differences are explained by differences in health 201 
care access (i.e., “health care access” hypothesis).  202 
For excess mortality, we assumed every province has the same risk as the 203 province with the highest risk, which is 83.2/100,000 in Gansu province12. A 204 total of four scenario analyses were performed in this study, with detailed 205 descriptions shown in Table 1.  206 
A systematic review demonstrated that the presence of “any risk factor” (using 207 the WHO risk factors definition26) was associated with an increased risk of 208 hospital admission (odds ratio 3·39, 95%CI 2·60-4·42) and death (odds ratio 209 2·04, 95%CI 1·74-2·39) in influenza-related patients30. 210 
2.2.3 Healthcare seeking behavior 211 
A household survey on health seeking behavior of adult patients with acute 212 respiratory infections carried out in China during 11/2009-03/2010, found that: 213 1) in urban areas, 9·7% of acute respiratory infection cases did not seek any 214 medical help, 66·0% self-medicated, or visited a doctor in community or 215 township health centers, and the remaining 24·3% visited a doctor in county or 216 higher level hospitals; 2) in rural areas, the relevant proportions were 217 respectively 8·6%, 79·0% and 12·4%31. We assumed that influenza patients have 218 the same healthcare seeking behaviors as acute respiratory infections cases. 219 
2.2.4 Influenza-related costs 220 
We used the average drug cost per outpatient in township healthcare centers 221 (US$ 5·4 in 2017) and that in community healthcare centers (US$11·9 in 2017) 222 as a proxy of the cost for self-medication of influenza patients in urban and rural 223 areas, respectively32. We previously found the treatment costs for influenza-224 
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related outpatients and inpatients aged 60 years old and over were respectively 225 US$129 (95% uncertainty interval, 95%UI 75-156) and US$2,735 (1,401-4,482) 226 in East China in 201333. The costs were extrapolated to other regions in China in 227 proportion to the regional GDP per capita.  228 
We also considered the lost productivity due to premature mortality attributable 229 to influenza, which was estimated using the friction cost method. The length of 230 the friction period was assumed to be three months, the elasticity of labor time 231 versus production assumed to be 0·8, and the costs of filling a vacancy and 232 training new personnel estimated to be US$357 in 200934,35. The yearly income 233 per capita of older adults (urban US$3,896; rural US$1,241) was obtained from 234 the fourth survey of the living conditions of older adults in urban/rural China in 235 201436. The labor force participation rates of older adults were derived from the 236 2010 Population Census of China25. All costs were adjusted and converted to US 237 dollars in 2017 using the consumer price index and the exchange rate of 1 US$= 238 6·75 CNY37. 239 
2.2.5 Quality-adjusted life years (QALYs) lost 240 
The number of QALYs lost due to influenza was calculated as the sum of QALYs 241 lost due to non-fatal episodes plus life years lost due to fatal episodes. The 242 duration of non-fatal episodes was assumed to be respectively 6·2 days (standard 243 deviation, 2·2) and 16·0 days (10·7) for influenza-related outpatients and 244 inpatients. Their associated health utility was separately estimated to be 0·5733 245 (95%UI 0·4650-0·6608) and 0.4128 (0·1793-0·6380)38. The background health 246 utility (urban 0·7719-0·8071; rural 0·6943-0·7434) was obtained from the China 247 Health and Retirement Longitudinal Study39.  248 
Life years lost due to fatal episodes were estimated based on risk-, area- and age-249 specific life expectancy. Life expectancy was calculated using the life table 250 approach and mortality data in 2017 from China Health and Family Planning 251 
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Statistical Yearbook32,40. Life years lost were discounted at an annual rate of 252 3%41. (Supplementary Materials 6) 253 
2.2.6 Vaccine effectiveness and cost 254 
A recent meta-analysis of test-negative design case-control studies indicated that 255 influenza vaccine is effective against laboratory confirmed influenza (odds ratio 256 0·48; 95% CI 0·39-0·59) in older adults when the vaccine strains closely match 257 the circulating influenza viruses, and also had significant effectiveness when 258 vaccine is poorly matched (odds ratio 0·64; 95% CI 0·52-0·78)42. We 259 conservatively used the efficacy of poorly-matched vaccines in the baseline 260 analysis. Adverse effects associated with influenza vaccination were not 261 considered as serious adverse events are extremely rare43. 262 
The procurement cost of influenza vaccination (not including vaccine logistic and 263 administration costs) in 2013 was US$5·73 per dose (95%UI 5·43-6·03) for the 264 0·50ml formulation Trivalent Inactivated influenza Vaccine14. 265 
2.3 Outcomes measures 266 
In this study, we calculated the incremental costs per QALY gained of vaccination, 267 and evaluated the health and economic impact of fully-funded influenza 268 vaccination at the national and seven regional levels, respectively. Because China 269 does not have an official threshold for cost-effectiveness, we used a willingness-270 to-pay threshold of the GDP per capita (US$8,840 in 2017) in the base case 271 analysis, and a more stringent threshold of US$3,780-US$5,880 per QALY gained 272 proposed by University of York economists44 to construct cost-effectiveness 273 acceptability curves. Due to the unavailability of vaccine logistic and 274 administration costs, only vaccine procurement costs were included in the base 275 case and sensitivity analyses. We further performed analyses for threshold 276 vaccination costs (TVC), below which fully-funded vaccination program would be 277 
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considered cost-effective. 278 
2.4 Sensitivity analysis 279 
We performed probabilistic sensitivity analyses to explore the influence of all 280 parameters on ICERs. This was done using Monte Carlo sampling with applicable 281 distributions for different parameters (Table 2), drawing 10,000 samples, then 282 calculating the median, and 95% UIs for the ICERs based on the 2·5th and 97·5th 283 percentiles of the 10,000 simulations. Scenario sensitivity analyses were also 284 conducted:1) from the health system perspective (only considering the direct 285 medical costs for influenza patients), 2) using well-matched vaccine effectiveness 286 42, and 3) using a discount rate of zero for QALYs loss as recommended by WHO 287 guidelines45. 288 
3. Results 289 
3.1 Impact and cost effectiveness in the base case scenario 290 
At the national level, a total of 63·4 million older adults in China are expected to 291 be vaccinated annually. Vaccination is expected to prevent 19,812 (95%UI 7,150-292 35,783) influenza-related ILI outpatient consultations, 9,418 (3,386-17,068) 293 influenza-related SARI hospitalizations and 8,800 (5,300-11,667) influenza-294 related deaths due to respiratory diseases, with 40%, 69% and 57% occurring in 295 high-risk groups (Figure 2 an S4).  296 
The fully-funded vaccination program is estimated to cost US$ 363 (344-382) 297 million, but gain 70,212 (42,106-93,635) QALYs, 98% of which were due to 298 influenza-related excess deaths averted (Figure 2). 38% of the increment cost, 299 and 54% of incremental QALYs occurs in high-risk groups (Figure S4). Using the 300 GDP per capita as a threshold, the fully-funded vaccination in older adults in 301 China is cost-effective with an ICER of US$4,832 (3,460-8,307) per QALY gained. 302 The TVC is US$10·19 (6·08-13·65), under which the fully-funded vaccination 303 
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program is cost effective using GDP per capita as the willingness-to-pay 304 threshold (Figure 3). 305 
Substantial variations in health and economic outcomes are observed across 306 regions (Figure 2). Except in Northeast China (US$8,945), the median ICER 307 (US$2,691-7,115) is below the GDP per capita and hence cost-effective. The TVC 308 in Northeast and Central China is lower than the national average, decreasing to 309 US$5·66 (3·41-7·70) and US$7·06 (4·15-9·66) (Figure 3).   310 
3.2 Probabilistic sensitivity analyses 311 
At the national level, 98% of Monte Carlo samples are considered cost-effective 312 under base case assumptions with a threshold of GDP per capita. However, 313 significant differences are observed for regions. For Northeast and Central China, 314 the proportion respectively reduces to 48% and 82%. While for other regions, 315 the probability is over 96% (Figure 4). Using a much more stringent threshold of 316 US$3,780-5,880 per QALY gained44, the probability of cost-effective for 317 vaccination decreases to 9%-80% at the national level. Similar patterns are 318 observed across regions (Figure S6). 319 
3.3 Scenario analyses 320 
Compared to the base case scenario, the influenza-related excess mortality due to 321 respiratory diseases increased 1-3 fold in Central, Northeast and Southwest 322 China, while only 47%-86% for other regions in scenario 1 and 2 . The low 323 probability of being cost-effective (around 48%) is only observed for Northeast 324 China in base case and scenario 2 (Figure 4). Compared to the base case scenario, 325 TVC increases by 55%-330% in scenario 1 and 2, and 4%-24% in scenario 4, 326 while decreases slightly in scenario 3 (Figure 3). 327 
Compared to the societal perspective analysis above, ICERs increase slightly 328 (mostly by <10% depending on region and scenario) from a healthcare provider 329 
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perspective (Figure S7-9). Vaccine effectiveness and discount rate have a high 330 impact on ICERs. When the vaccine is well matched circulating influenza strains, 331 the fully-funded vaccination program is 100% cost effective across all regions 332 (Figure S10-12). When the discount rate for QALYs loss is zero, the fully-funded 333 vaccination program is cost effective across all regions, at a probability of >90% 334 except for Northern China in base case and scenario 3 (around 80%)(Figure S13-335 15). 336 
Compared to the base case analysis (with a mismatched vaccine and a discount 337 rate of 3%) from the societal perspective, the TVC decreases by less than 5% 338 from the healthcare provider perspective, while it increases by 44%-45% when 339 vaccine strains match the circulating strains, and increases by 18%-21% when 340 discount rate is zero for QALYs loss (Figure 3). 341 
4. Discussion  342 
The provision and management of vaccines in China is currently undergoing 343 regulatory reforms16,46. Expanding China’s government-funded vaccination 344 programs is now recommended by both WHO and the State Council of China17,47. 345 In 2019, the influenza vaccine was one of the vaccines that went through 346 comprehensive evaluation by the National Immunisation Advisory Committee of 347 China for inclusion into the National Immunisation Program as a fully 348 government-funded vaccine. A first step towards this could be considering 349 vaccination for older adults due to their higher risk of influenza-related 350 hospitalization and mortality. Our analysis comprehensively evaluates the health 351 and economic impact of a potential fully-funded influenza vaccination program in 352 older adults. It shows that vaccinating older adults in China is cost-effective, with 353 an ICER of US$ 4,832 per QALY gained (lower than GDP per capita), despite 354 conservative assumptions about vaccine effectiveness assumed in the base case 355 scenario. However, we find that variations in health and economic impact exist 356 across regions. 357 
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In our study, the fully-funded vaccination program could reduce both QALY loss 358 and productivity loss due to premature deaths. While productivity loss only 359 contributes to <2% of the decrease in total costs , the relevant QALY loss averted 360 contributes to >96% in total QALYs saved. Accordingly, variation in influenza-361 related respiratory excess mortality across regions is a significant factor for 362 different ICERs observed here (base case vs. scenario 1, and 2). Our analysis 363 demonstrates that in the base case analysis, the probability of being cost-effective 364 for the fully-funded influenza vaccination program is much lower in regions with 365 lower reported mortality burden than that with heavy influenza excess mortality 366 burden (e.g., lower in Northeast compared to. Northern China) 12. The influenza 367 mortality in Northeast China may genuinely be lower due to lower population 368 density and reduced air pollution. On the other hand, it may simply appear lower 369 due to factors such as patients seeking advanced healthcare in neighbouring 370 developed regions12 and poor quality of influenza and death surveillance. Since 371 the two sets of potential reasons for lower mortality are difficult to disentangle, 372 we should be very cautious in interpreting regional-level economic results. This 373 highlights the importance of improved influenza surveillance, particularly in less 374 developed regions of China, in order to better target influenza control programs. 375 Variations in influenza-related ILI consultation only have slightly impact on the 376 ICERs (base case vs. scenario 4).  377 
In Northeast China, the fully-funded influenza vaccination program is considered 378 cost-effective if TVC is respectively below US$5·7 in the base case analysis. We 379 used the private sector vaccine cost in the model, which is US$5·73 per dose 380 currently14, much higher than most of the vaccines currently used in the National 381 Immunisation Program48. Several Chinese manufactures produce influenza 382 vaccines in Northeast China43. A government-funded influenza vaccination 383 program using local manufactures’ vaccines is likely to have lower delivery costs 384 due to economies of scale and lower procurement costs due to increased 385 consumer bargaining power. That will certainly increase the likelihood that the 386 
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fully-funded influenza vaccination is cost-effective in this region. 387 
Only one study to date has assessed the cost-effectiveness of influenza 388 vaccination among older adults in China49. This study had a number of 389 limitations: (i)it used influenza-related outpatient and hospitalization rates in 390 the US, which may not be good proxies for relevant rates in China due to the 391 different influenza seasonality, virus activity, and health seeking behavior, etc.21 392 And (ii) it used influenza-related mortality before 2009 influenza pandemic in 393 China, even though the burden has changed due to the displacement of seasonal 394 A(H1N1) virus after pandemic11,12. With these shortcomings, the paper suggested 395 that government-funded influenza vaccination was <50% likely to be cost-396 effective, when compared to a threshold of one times GDP per capita. In our 397 study, we used the most recent China-specific post-2009 pandemic data, 398 including influenza-related outpatient, hospitalization and mortality rates. 399 
The number of excess respiratory deaths29 used in this study may not fully 400 capture all influenza–associated deaths because influenza virus infections not 401 only cause respiratory deaths, but also deaths from other diseases such as 402 cardiovascular diseases, diabetes, and renal diseases11. Accordingly, vaccination 403 could be even more cost-effective than presented here. 404 
A limitation of our study is that the influenza-related SARI hospitalization rate is 405 only available in one city each in Southern and Northern China9,10. These two 406 cities may not fully represent the hospitalization rate across China. We used the 407 ratio of the influenza-related SARI hospitalization rate to influenza-related ILI 408 consultation rate separately in Jingzhou, Hubei and Beijing as a multiplier to 409 estimate the influenza-related SARI hospitalization rate for the rest of Southern 410 and Northern China, respectively. However, it may not be a good proxy due to 411 different health seeking behaviors especially between areas with varying levels 412 of socioeconomic development, and health service provision. 413 
16 
 
 
China's first vaccine administration law allows provincial governments to add 414 additional vaccines into their local fully-funded vaccines list on the basis of local 415 disease burden18. Until now, only a few highly-developed provincial- and 416 prefecture-level cities have offered fully-funded influenza vaccination for older 417 adults (e.g., Beijing and Shenzhen).These local initiatives have achieved 418 remarkable increases in local vaccine uptake14,15. However, expanding such fully-419 funded vaccination to the entire population or even large regions of China would 420 require large budget allocations. Because of that, there is a need for detailed cost-421 effectiveness analysis to determine if such a move is good value for money. Hence 422 our results fill a key evidence gap needed by decision-makers in China. Due to 423 large apparent variations in influenza disease burden, and socioeconomic 424 development level across regions, our regional analyses could also provide 425 information on the cost-effectiveness of fully-funded influenza vaccination that 426 may be relevant to other countries with similar disease burden and economic 427 status, especially low- and middle-income countries where cost-effectiveness 428 analysis is limited20. 429 
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Research in context 430 
Evidence before this study 431 Seasonal influenza vaccination in older adults has been found to be cost-effective 432 in many middle- and high-income countries, and has been introduced into the 433 vaccine schedules of many such countries. In contrast, in most of China influenza 434 vaccines are only available in the private sector and have very low uptake, even 435 though China has more adults aged 60 years and over than any other country and 436 is ageing rapidly. A previous systematic review (Pan X, et al. Systematic review of 437 economic evaluations of vaccination programs in mainland China: Are they 438 sufficient to inform decision making? Vaccine, 2015.) shows no cost-effective 439 analysis of influenza vaccination in older adults has been conducted in mainland 440 China till August, 2015. We further searched PubMed, China National Knowledge 441 Infrastructure and Wanfang between August 4, 2015 and November 20, 2019, 442 
using MeSH terms and key words, including “influenza”, “vaccine”, “economic 443 
evaluation” or “cost”, and “China”. Only one study in Chinese (Chen C, et al. 444 Cost‑ effective analysis of seasonal influenza vaccine in elderly Chinese 445 population. Chin J Prev Med, 2019) has been published. This used influenza 446 outpatient and hospitalization burden in the US as a proxy for the burden in 447 China to evaluate the government-funded influenza vaccination programme 448 among the older adults at the national level. The study found that government-449 funded influenza vaccination has a low probability of being cost-effective (<50%) 450 when using one times GDP per capita as the cost-effectiveness threshold.  451 
Added value of this study 452 We assessed the epidemiological impact and cost-effectiveness of a potential 453 government fully-funded influenza vaccination program using China-specific 454 disease burden of influenza at both the national and regional level. Our findings 455 show that vaccination program is cost-effective at the national level in China. 456 However, variations exist among geographic regions, with Northeast China 457 
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having a lower probability of being cost-effective. However, this may be at least 458 partly due to differences in surveillance quality across regions. In Northern 459 China, the fully-funded influenza vaccination program is cost-effective if 460 vaccination cost is below US$5·66. 461 
Implications of all the available evidence 462 Our findings support implementing a fully government funded influenza 463 vaccination program in mainland China. It also highlights the variation in health 464 and economic effects of vaccination across China due to variations in influenza 465 seasonality, disease burden, demographic structure, and socioeconomic 466 development. These results are likely to be vital for policy making since the State 467 Council of China has recommended acceleration of the inclusion into the national 468 immunization program of vaccines currently sold in the private sector. 469 
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Table 1. Description of base case and scenario analyses. 
Analyses Influenza-related ILI consultation 29 Influenza-associated excess mortality attributable to respiratory diseases 12 
Base case Used original rate as reported for each province in the literature Used original rate as reported for each province in the literature 
Scenario 1 
Used original rate as reported for each province in the literature, and assumed the difference between any other province and Shanghai is due 
to difference in health care access (i.e., “health 
care access” hypothesis) 
Assumed every province has the same risk as Gansu Province, with the highest rate of 83.2/100,000 
Scenario 2 Assumed every province has the same risk as Shanghai, with the highest rate of 690/100,000 Assumed every province has the same risk as Gansu Province, with the highest rate of 83.2/100,000 
Scenario 3 
Used original rate as reported for each province in the literature, and assumed the difference between any other province and Shanghai is due 
to difference in health care access (i.e., “health 
care access” hypothesis) 
Used original rate as reported for each province in the literature 
Scenario 4 Assumed every province has the same risk as Shanghai, with the highest rate of 690/100,000 Used original rate as reported for each province in the literature 
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Table 2. Key model parameter distributions. Parameter Mean (Range/SD)* Distribution  Proportion of high-risk groups Supplementary Materials 4, Fig S3 Beta Flu-related ILI consultation rate29 Supplementary Materials 5, Table S2 Normal Flu-related SARI hospitalization (per 100,000)9        Beijing (2013-2014) 105 (95%CI 85-129) Normal with μ=105, sd=11·22      Beijing (2014-2015) 66 (95%CI 50-86) Normal with μ=66, sd=9·18      Jingzhou, Hubei province (2011-2012) 89 (95%CI 85-90) Uniform (min=85/100,000, max=90/100,000) Flu-related respiratory excess mortality12 Supplementary Materials 5, Table S2 Lognormal Healthcare seeking behaviour (%)31         Probability of no-healthcare-use Urban: 9·7,  Rural: 8·6 Urban: Dirichlet with α1=107, 
α2=704, α3=269,  
Rural: Dirichlet with α1=43, 
α2=394, α3=62 
     Probability of self-treatment,       seeking care in Community          /Township Health Service Centers  Urban: 66·0,  Rural: 79·0      Probability of visiting doctors in       county-level and above hospitals Urban: 24·3,  Rural: 12·4 Odds ratio of influenza-related hospitalization in high-risk groups compared to low-risk groups30 3·39 Lognormal with μ=1·22, sd=0·14 Odds ratio of influenza-related death in high-risk groups compared to low-risk groups30 2·04 Lognormal with μ=0·71, sd=0·08 Vaccine cost (US$ in 2013)14 5·73 (95%UI 5·43-6·03) Bootstrap from data on influenza vaccine cost Influenza outpatients visits and hospitalization costs(US$ in 2013)33 Outpatients: 129 (95%UI 75-156) Inpatients: 2,735 (95%UI 1,401-4,482) Bootstrap from data on national retrospective survey Duration of influenza episode for outpatients and inpatients (days)38 Outpatients: 6·2 (SD 2·2)  Inpatients: 16·0 (SD 10·7) Bootstrap from data on national retrospective survey 
Utility of influenza outpatients and inpatients38 Outpatients: 0·5733 (95%UI 0·4650-0·6608)  Inpatients: 0·4128 (95%UI 0·1793-0·6380) Bootstrap from data on national retrospective survey 
Background health utility39  
Urban   60-74 years: 0·8071 (SD 0·0039); 
≥75 years: 0·7719 (SD 0·0093) Rural 60-74 years: 0·7434 (SD 0·0031); 
≥75 years: 0·6943 (SD 0·0078) 
Normal distribution 
Risk of infected from influenza in vaccinated group vs. unvaccinated group (Odds ratio)42 0·64 (0·52-0·78) Lognormal with μ=-0·45, sd=0·10 * used in one-way sensitivity analysis. SD denotes standard deviation; 95%CI denotes 95% confidence interval; 95%UI denotes 95% uncertainty interval calculated by bootstrap methods.
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Figure captions 
Figure 1. Decision tree model for influenza vaccination in older adults. Chance node 2 is the same as chance node 1, and chance node 4 is the same as chance node 3. Figure 2. Epidemiological and economic impact of fully-funded influenza vaccination program in older adults, stratified by geographic regions, China Figure 3. Threshold vaccination costs (TVC) Figure 4. Monte Carlo simulation results on the cost-effectiveness for fully-funded vaccination program compared to self-paid vaccination program (grey line denotes China's GDP per capita in 2017 and circle denotes the 95%UI) 
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